Apogee Therapeutics Announces Pipeline Progress, Reports Second Quarter 2024 Financial Results

Continued pipeline progress and execution toward anticipated milestones including APG777 16-week proof-of-concept data from the Phase 2 Part A study in 2H 2025, APG808 interim Phase 1 data in 4Q 2024 and APG990 Phase 1 study initiation in healthy volunteers accelerated to 3Q 2024

APG333, a novel subcutaneous anti-TSLP antibody with extended half-life, added to the portfolio to provide potential combination of best-in-class efficacy across multiple respiratory indications, expected to enter the clinic in 2025